WeightWatchers names new medical chief, plans to offer menopause therapy and support
Reuters exclusively reported the appointment earlier in the day.
Boyd, a Stanford University graduate who has worked with several consumer health startups, said in an interview WeightWatchers is building upon its decades-long work providing weight management tools to also address the specific needs of people using obesity treatments. That includes Novo Nordisk's NOVOb.CO Wegovy and Eli Lilly's (LLY.N), opens new tab Zepbound.
The company says its model promoting balanced eating and exercise helps subscribers reduce gastrointestinal side effects from the medicines and lose more weight on Wegovy.
"We have the foundation, and we will continue to evolve our programming to show up in a way that matches best with the addition of medications," Boyd said.
WeightWatchers CEO Tara Comonte said such support for members using weight-loss drugs should appeal to health insurers and employers who pay for health benefits as they seek more sustainable management of the costly medications.
"It's a different business model and these partnerships and relationships take a much longer period of time than dialing up some direct to consumer marketing or promotional models," Comonte said.
The program for perimenopause, menopause and post-menopause will include access to prescription treatments such as hormone replacement therapy, as well as behavioral and nutritional support for members, a significant proportion of whom are women ages 40 to 60 years old, WeightWatchers said.
More details will become available later this year, the company, also known as WW International, said.
'It is a very natural overlap. In the perimenopausal and menopausal phase, up to 70% of women experience weight gain,' Boyd said.
Boyd previously served as national medical director at One Medical, a clinical business now owned by Amazon.com (AMZN.O), opens new tab, and later was chief medical officer at weight-management company Calibrate.
Her appointment comes nearly a year after previous Chief Medical Officer Dr. Amy Meister stepped down. In the interim, WeightWatchers emerged from Chapter 11 bankruptcy, after struggling to compete with other online weight-management platforms selling cheaper, compounded versions of obesity treatments, including telehealth companies like Hims & Hers Health (HIMS.N), opens new tab.
The market for weight-management companies is changing since the U.S. Food and Drug Administration ordered an end to sales of compounded versions of Wegovy in late May. WeightWatchers last month announced a partnership with Novo Nordisk to sell Wegovy through the drugmaker's NovoCare pharmacy.
Hims & Hers continues to offer smaller doses of compounded Wegovy than what is available from Novo, arguing they are providing a personalized medication that is not subject to the FDA ban. Industry analysts, however, have questioned whether that strategy will leave Hims vulnerable to legal challenges.
Hims has said it also plans to expand into testosterone and menopause treatments as part of its growth strategy in the coming years.
WeightWatchers has stopped selling compounded weight-loss drugs, and its partnership with Novo may prove more attractive to employer-sponsored health plans in the long run, Boyd said.
"At the foundation of this is prescribing FDA-approved medications," Comonte said. 'We only prescribe branded drugs."
A month's supply of Wegovy is listed at over $1,000 per month, but many people pay less through insurance. Cash-pay patients can access the treatment for $499 through NovoCare.
"For employers, some of them are finding value in these vendors like WeightWatchers... that give the members the lifestyle tools," said Chantell Reagan, a senior director at advisory firm Willis Towers Watson.
These strategies may help an employee sustain weight loss if they stop using a drug, she said. "We are looking very closely at our employers that are using these programs and assessing the effectiveness."
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Independent
41 minutes ago
- The Independent
FDA warns lead could be leaching into food from this cookware
The Food and Drug Administration has warned lead could be leaching into food from certain imported cookware. The FDA had tested cookware products from the Indian company Saraswati Strips and found them to leach lead into food when used for cooking, according to a new warning. The affected product is called a kadai or karahi, which is a deep pan, similar to a wok. These pans were made from aluminum, brass, and aluminum alloys known as Hindalium/Hindolium or Indalium/Indolium. The FDA does not authorize the use of lead in cookware so it has advised retailers not to sell the pans and consumers not to use them. The pans have been sold at Mannan Supermarket in Queens, New York. Lead is toxic to people of any age or health status, but 'young children, women of child-bearing age, and those who are breastfeeding may be at higher risk for potential adverse events after eating food cooked using these products,' the administration warned. Low levels of lead exposure can cause children to experience trouble learning, low IQ, and behavior changes, the FDA says. Higher levels of lead exposure can cause people to experience fatigue, headache, stomach pain, vomiting and neurological changes, according to the administration. The FDA advised consumers to throw away any cookware that could leach lead into food, either when cooking or when used for food storage. The administration explicitly says not to donate or refurbish the affected cookware. People who are concerned about lead exposure should contact a health care provider, the FDA warned. The administration is working to remove the cookware from the U.S. market as it has yet to identify and contact the distributor to initiate a recall. Saraswati Strips says on its website it manufactures cookware 'from finest quality aluminum' that is 'subjected to stringent process controls at all stages of production for absolute hygienic performance rendering them completely safe for cooking and storage purposes.'
The Guardian
2 hours ago
- The Guardian
Ozempic didn't work for me. I was furious
I'm 46 years old and I have been on a diet since I was 11. For as long as I can remember, eating has given me comfort. As a kid, I lied to my friends' parents so I could eat a second dinner at their house. I've never wanted just one cookie – I'd eat 12 and only stop when I felt physically ill, and sometimes not even then. In nearly every photo of me as a teenager I'm wincing, sucking in my stomach, trying to pose. I never really enjoyed the taste of these foods, nor was I happy with myself after eating them. They came with a side of guilt: you don't deserve this. This relentless food noise trapped me in a cycle of wanting to eat, then shaming myself for doing it. I spent inordinate energy hating my too tall, too big body. I always felt simultaneously like not enough and too much. Now, GLP-1 drugs like Ozempic, Wegovy and Mounjaro are being hyped as an easy fix to obesity. Their manufacturers have experienced significant revenue growth credited to the drugs' popularity; for instance, Eli Lilly recently announced 38% yearly growth, credited in part to sales of Zepbound and Mounjaro. Media headlines tout the changes in weight and appetite for those who take them. But what if the 'miracle' doesn't work for you? Being diagnosed with diabetes at age 27 threw me deeper into a shame spiral. At the time, my doctor clinically defined me as obese. That, along with the prognosis of a deficient pancreas, felt like punishment for decades of failing to control my overeating. Given my family history of diabetes – my grandpa had it – the doctor diagnosed me as type 2 and recommended dramatic lifestyle adjustments, including carb counting and daily exercise. She also did an A1C test, which measures average blood sugar levels for three months. A non-diabetic's result would be under 5.7%. Mine was 7.7%. This diagnosis felt like being sentenced to lifelong obsession. Food already controlled me, and now it had even more power. Over the next five years, I worked with a nutritionist and psychotherapist. I trained for a 200-mile relay race with friends. I did Weight Watchers, went to Overeaters Anonymous, worked the 12-step program, and used apps like Noom and My Fitness Pal. I lost 50lb. Still, I remained overweight according to the BMI chart, and my A1C didn't budge, which confounded my primary care doctor. She referred me to an endocrinologist who specialized in metabolic health. Six months later, when my appointment finally arrived, my A1C had shot up to 9.1%. That should not have happened while I shed pounds. She declared I was misdiagnosed: type 2 diabetics' bodies make insulin, which helps regulate blood sugar, but don't use it effectively. But I was actually type 1, an autoimmune condition where the body stops producing insulin. I would be dependent on insulin injections from that point forward. Living with diabetes was taxing. I had to order a continuous glucose monitor (CGM), pen needles, insulin vials and other items – but via a specialty supplier rather than a standard pharmacy, for insurance purposes. I had to procure pre-authorization forms for medication and attend required half-day training sessions every time I wanted to try a different insulin pump or when my insurance changed. In 2018, after five years of effort, my A1C settled in at 5.9% – a happy result for me and my doctor. But to get to a weight my doctor would approve, I still had to lose 30lb. She started me on a new drug called Ozempic. Like most people at that point, I'd never heard of it. She said it was only technically approved for type 2 patients – but some who were overweight with type 1, like me, were taking it to help with weight loss. Over the next four years, my doctor and I gradually increased my Ozempic dosage and eventually were pleased with the results: when I woke in the morning my fasting blood sugar reading was finally within the recommended range of 80-120 on my CGM. I was able to reduce my regular insulin usage. But my weight didn't change. I continued my healthier eating habits and exercised regularly with cycling, yoga and running. Still, the scale didn't move. In 2022, when Ozempic was becoming a household name, I suddenly had two problems. First, my doctor confirmed I was already on the highest available dose, so taking more wouldn't help me lose weight. Second, because the drugs were now approved for general weight loss, I might have trouble filling my prescription. A global shortage followed, and I went four months without, eventually switching to Mounjaro because it was available. My already-thin friends started taking GLP-1s, and I couldn't avoid chatter about the 'skinny shot'. 'I'm not even hungry! I don't even think about food!' they'd say. But I didn't experience this quieting of the voices in my head telling me I was hungry all the time, and I wondered why. I was furious. As my friends celebrated their new bodies, I wondered, again, what was wrong with mine. My diabetes was under control, but I was also existing at the margins of a miracle. An estimated 15% of all GLP-1 users are so-called 'non-responders' to the weight loss effect, according to Atlanta-based physician Dr Cristina Del Toro Badessa. Lucas Veritas, a GLP-1 user from Montreal and author of The GLP-1 Effect newsletter, highlighted clinical trials showing that approximately 13% of people taking semaglutide (the active ingredient in Ozempic and Wegovy) and about 9% of those taking tirzepatide (found in Mounjaro and Zepbound) did not lose more than 5% of their body weight. 'The meds are highly effective for a majority of patients but there is still a percentage who don't lose a clinically significant percentage of body weight. Everyone's physiology is a little different,' said Veronica Johnson MD, an obesity medicine specialist in Chicago. Recent research has identified a gene that may help predict who will successfully lose weight with GLP-1 medications. Sign up to Well Actually Practical advice, expert insights and answers to your questions about how to live a good life after newsletter promotion Additionally, according to a recent study comparing GLP-1 medications to bariatric surgery, 'real world' cohorts lost less weight than what drug companies reported in their trials: about 5% of their body weight, compared with the 15% reported for semaglutide and the 20–25% for tirzepatide in pharma-funded studies. Nicoletta LaMarca-Sacco, 56, a former Ozempic user in New York, also didn't lose weight after a year of use. 'I've always been a squishy mom and will continue to be,' she said. 'It just didn't work for me.' She expected the drug would quiet more of the internal chatter telling her she needed to snack. 'It did help, but only to a small degree,' she said. 'When we consider these drugs, they need to be combined with other markers of good health like diet, exercise, even stress management,' said Dr Raj Dasgupta, an ABIM Quadruple board-certified physician in Los Angeles. He said his patients sometimes had unrealistic expectations about how quickly and dramatically they will drop extra pounds. He explained that for someone who is overweight, shedding even a small amount of weight can improve heart and kidney function, adding: 'The bar has been set too high for weight loss.' 'What's dangerous,' Badessa said, 'is the dominant societal narrative that these are 'magic shots' for weight loss.' Veritas agreed: 'Expectations are sky-high. People see all the before/after photos and expect an easy ride.' 'It feels similar to any other time the diet industry has thrown marketing momentum behind one particular 'fix',' Virginia Sole-Smith, author of Fat Talk, told me about the current hype. 'There's excitement that we've found a 'silver bullet', then it silences any other narratives and experiences about it.' I had definitely been looking for an elixir to rid me of body mass. Then I discovered that diabetes itself might be the reason I wasn't losing weight. Andrew Koutnik, a metabolic research scientist, said that GLP-1s typically lead to significant weight loss for people with obesity (15-25% of their body weight). However, people with diabetes generally lost less weight, proportionally: for type 2, an average of 8-11%; for type 1, about 8-12%. 'While we don't know why this is occurring, prior data suggests the drug's metabolic effects may be tied to how well the body manages glucose,' Koutnik said. GLP-1s are designed to coax the body into making and using insulin more efficiently, he explained. But for someone with type 1 diabetes, meaning their pancreas cannot make insulin, that's like installing a turbocharger on a car with no engine – there's nothing to boost. That said, he clarified, these drugs aren't entirely useless for people with type 1. GLP-1s slow digestion and suppress appetite, which can lead to fewer snacks and less carb-heavy meals. That might nudge blood sugar in the right direction, but it's more of a side-effect. 'The actual impact on blood sugar control is minimal: less than a 1% drop in A1C,' Koutnik explained. The psychological fallout of being a non-responder can be devastating. It was more fodder for my destructive inner dialogue: Why won't my body just comply? Alyson Curtis, a therapist based in New York, works with patients who feel isolated as they see others losing weight and don't have the same result. I told her how unfair it felt and she agreed the loss of agency can be a lot to process. 'I hear the 'thin fantasy' constantly from patients – it's a dream to fit into societal norms,' Curtis added, 'but what they're really saying is they want to be accepted, cherished, adored.' She helps patients reframe success to focus on healthy outcomes beyond weight loss – like how the Health at Every Size (HAES) movement centers on overall wellbeing. Still, these drugs are here to stay. Johnson pointed to recent innovations like CagriSema, a compound drug bringing together an amylin agonist and a GLP-1. In trials, CagriSema helped reduce blood sugar spikes after meals and can also contribute to weight loss. 'The hormone called amylin is normally released by the same cells that make insulin – which type 1 diabetics lack,' Koutnik said. He added that amylin helps slow digestion and also lowers levels of glucagon, which could help better manage blood sugar. Society seems to have rewritten ideas about health, worth and willpower through the lens of these astonishing drugs. I figured I could, too. I've tried to quiet the inner voice that's shaming me into thinking I'm a failure for not losing more weight. Forging self-acceptance from deep frustration, I am realizing there is nothing inherently 'wrong' with my body – I am simply among those for whom the current medications produce a partial benefit. Learning that I'm not alone has helped curb my body shame. I am grateful that GLP-1s have helped me with blood sugar control, minimizing my risk of complications from diabetes. 'When we focus on the miracle weight loss narrative, we ignore their real value in helping people with diabetes, adding to the discourse of body shaming, which is never health-promoting,' said Sole-Smith. I've been trying to shift my focus from weight loss to improving my relationship with food. For me, that's learning to eat with more intention and maybe even a little joy. Hopefully, I can come to appreciate my right to the occasional indulgence without self-recrimination. And on my next birthday, I want to celebrate with the most delicious symbol of self-acceptance: a guilt-free piece of cake.
Daily Mail
2 hours ago
- Daily Mail
Jeff Bezos' mother Jackie has died
Published: | Updated: Amazon founder Jeff Bezos mourned the loss of his mother after she died surrounded by family in her Miami home at the age of 78. Jacklyn Bezos, also known as Jackie, died peacefully at home on Thursday, after a battle with brain illness, Jeff said in a post to his Instagram. 'After a long fight with Lewy Body Dementia, she passed away today, surrounded by so many of us who loved her — her kids, grandkids, and my dad,' Jeff Bezos wrote. 'I know she felt our love in those final moments. We were all so lucky to be in her life. I hold her safe in my heart forever.' Earlier the Bezos Scholars Program confirmed her passing in their own statement, writing: 'A quiet final chapter to a life that taught all of us, friends and family alike, the true meaning of grit and determination, kindness and service to others. Jackie's life of service was second only to her passion for family and gathering. As a grandmother Jackie found immense joy in watching her family grow. She passed down not only traditions and stories, but also her values - kindness, resilience, and the importance of togetherness.' Jacklyn had been diagnosed with Lewy Body Dementia in 2020, her foundation said, with her husband Mike remaining by her side throughout the struggle. The family acknowledged the team of health care professionals that had helped her over the last few years. News of her passing was shared by Bezos' wife Lauren Sanchez, who posted a picture of her mother-in-law on Instagram with a breaking heart emoji. After news of her passing was shared to social media by the Bezos Scholars, they were quickly inundated with tributes. News of her passing was shared by Bezos' wife Lauren Sanchez, who posted a picture of her mother-in-law on Instagram with a breaking heart emoji. After news of her passing was shared to social media by the Bezos Scholars, they were quickly inundated with tributes. 'I'm so honored I got to work with Jackie on the Bezos Scholars program and stay in touch with her and Mike. The universe is a better place for having had her in it,' one person commented. Another added: 'Jackie taught and lived by the ripple effect. The ripples she created will continue to magnify. How she touched so many lives.' Jacklyn had met Jeff's biological father Ted Jorgensen and gave birth to the billionaire at the age of 17, they had married the year previously. When Jeff was just 17 months old she filed for divorce from Jorgensen, later going on to marry Cuban refugee Miguel 'Mike' Bezos who adopted Jeff. The two share their son Mark. Jacklyn and Miguel went on to invest just under $250,000 into Amazon in 1995 to help their son with his new company. The sum that they lent him was considered not just a huge amount but also a massive risk as people were still skeptical of the internet. But the gamble paid off, as their son is now worth over $243 billion dollars - with Amazon a $2 trillion company. Bezos spoke about the original investment his parents gave him at a 2015 event, recalling telling them: 'I want you to know how risky this is. Because I want to come home at dinner for Thanksgiving and I don't want you to be mad at me.' It is unclear how much stock they still hold in the company, they donated just under 600,000 shares to the Bezos Family Foundation from 2001 to 2016 according to filings. In 2022, Bezos helped his parents snap up a six-bedroom, seven-bathroom waterfront mansion in Miami for $34 million. The property was bought by a Delaware company linked to Bezos' parents with the help of a $5million loan from the Bank of America. Jeff added to his own tribute: 'Her adulthood started a little bit early when she became my mom at the tender age of 17. That couldn't have been easy, but she made it all work. She pounced on the job of loving me with ferocity, brought my amazing dad onto the team a few years later, and then added my sister and brother to her list of people to love, guard, and nourish. For the rest of her life, that list of people to love never stopped growing. She always gave so much more than she ever asked for.'
